Recent developments in autoimmune liver diseases

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 9-10, 1997, Pages

  Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Auto antibodies; Autoimmune hepatitis; Autoimmune polyendocrine syndrome type 1; Chronic active hepatitis; Overlap syndrome; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

ANTINUCLEAR ANTIBODY; ASIALOGLYCOPROTEIN; AZATHIOPRINE; DIHYDRALAZINE; PREDNISOLONE;

AUTOIMMUNITY; CHOLESTASIS; CHRONIC ACTIVE HEPATITIS; CONFERENCE PAPER; DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; LIVER DISEASE; MALE; MULTIPLE ENDOCRINE ADENOMATOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SCORING SYSTEM; SYNDROME DELINEATION;

EID: 0030787147     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00509.x     Document Type: Conference Paper

References (141)

1. Waldenström J. Leber, Blutproteine und Nahrungseiweiß. Dtsch. Z. Verdau. Stoffwchselkr. 1950; 2: 113-9.
2. Kunkel HG, Ahrens EH Jr, Eisenmenger WJ et al. Extreme hypergammaglobulinemia in young women with liver disease of unknown etiology (abstract). J. Clin. Invest. 1951; 30: 654.
3. Bearn AG, Kunkel HG, Slater R. The problem of chronic liver disease in young women. Am. J. Med. 1956; 21: 3-15.
4. Mackay IR, Taft LI, Cowling DC. Lupoid hepatitis. Lancet 1956; 2: 1323-6.
5. Johnson PJ, McFarlane IG. Meeting Report of the International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998-1005.
6. Baggenstoss AH, Soloway RD, Summerskill WHJ et al. Chronic active liver disease. The range of histological lesions, their response to treatment and evaluation. Hum. Pathol. 1972; 3: 183-98.
7. Soloway RD, Summerskill WHJ, Baggenstoss AH et al. Clinical biochemical and histologic remission of severe chronic active liver disease: A controlled study of treatment and early prognosis. Gastroenterology 1972; 63: 820-33.
8. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-7.
9. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Büschenfelde K-H. Characterization of a new subgroup of autoimmune chronic active hepatitis by auto-antibodies against soluble liver antigen. Lancet 1987; 1: 292-4.
10. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 auto-antibodies recognize a short linear sequence in P450 II D 6, a cytochrome P450 monooxygenase J. Clin. Invest. 1991; 88: 1370-8.
11. Czaja AJ, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: A point of view. Am. J. Gastroenterol. 1995; 90: 1206-11.
12. Berg PA, Stechemessar E. Hypergammaglobulinämische chronisch aktive Hepatitis mit Nachweis komplementbindender partiell leberspezifischer Antikörper. Verg. Dtsch Ges. Inn. Med. 1981; 87: 921.
13. Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 1993; 18: 1-9.
14. Treichel U, Portalla T, Hess G, Manns M, Meyer zum Büschenfelde KH. Auto-antibodies to human asialoglycoprotein receptor in autoimmune-type chronic active hepatitis. Hepatology 1990; 11: 606-12.
15. Martini E, Abuaf E, Cavalli F et al. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988; 8: 1662-6.
16. Nishioka M. Nuclear antigens in autoimmune hepatitis. In: Meyer zum Büschenfelde KH, Hoofnagle J, Manns M, eds. Immunology and Liver. London: Kluwer Academic Publishers, 1993; 193-205.
17. Strassburg CP, Alex B, Zindy F et al. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases. J. Hepatol. 1996; 25: 859-66.
18. Kurki P. Cytoskeleton antibodies in chronic active hepatitis. In: Meyer zum Büschenfelde KH, Hoofnagle J, Manns M, eds. Immunology and Liver. London: Kluwer Academic Publishers, 1993; 206-14.
19. Czaja AJ, Cassani F, Cataleta M, Valenti P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996; 24: 1068-73.
20. Homberg JC, Abuaf N, Bernard O et al. Chronic active hepatitis associated with anti-liver/kidney microsome antibody type I: A second type of 'autoimmune hepatitis'. Hepatology 1987; 197: 1333-9.
21. Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin. Exp. Immunol. 1973; 15: 331-44.
22. Codoner-French P, Paradis P, Gueguen M et al. A new antigen recognized by anti-liver microsome antibody (LKMA). Clin. Exp. Immunol. 1989; 54: 232-8.
23. Manns M, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. The major target antigen of liver kidney microsomal auto-antibodies in idiopathic autoimmune hepatitis is cytochrome P450 db1. J. Clin. Invest. 1989; 83: 1066-72.
24. Abuaf N, Johanet C, Chretien P et al. Characterization of liver cytosol antigen type 1 reacting with auto-antibodies in chronic active hepatitis. Hepatology 1992; 16: 892-8.
25. Zanger UM, Hauri HP, Loeper J et al. Antibodies against human cytochrome P450 db 1 in autoimmune hepatitis type II. Proc. Natl Acad. Sci. USA 1988; 85: 8256-60.
26. Gueguen M, Yamamoto AM, Bernnard O, Alvarez F. Antiliver kidney microsome antibody type 1 recognizes cytochrome P450 db1. Biochem. Biophys. Res. Comms. 1989; 159: 542-7.
27. Manns M, Zanger U, Gerken G et al. Patients with type II autoimmune hepatitis express functionally intact cytochrome P450 db1 that is inhibited by LKM1 auto-antibodies in vitro but not in vivo. Hepatology 1990; 12: 127-32.
28. Gonzalez FJ, Skoda RC, Kimura S et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331: 442-6.
29. Yamamoto AM, Crestil D, Homberg JC, Alvarez F. Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus positive and negative sera. Gastroenterology 1993; 104: 1762-7.
30. Manns MP, Kaletzko S, Löhr H et al. Discordant manifestation of LKM-1 antibody positive autoimmune hepatitis in identical twins. Hepatology 1990; 12: 840.
31. Choudhury K, Gregorio GV, Mieli-Vergani G, Vergani D. Structural similarity and humoral crossreactivity in target antigens of organ specific autoimmune disease. Proceedings of the 29th Annual Meeting and Postgraduate Training Course of the European Society for Paediatric Gastroenterology and Nutrition in Munich, 1996, p. 79.
32. Duclos-Vallee JC, Hajoui O, Yamamoto AM, Jacqz-Aigrain E, Alvarez F. Conformational epitopes on Cyp 2D6 are recognized by liver/kidney microsomal antibodies. Gastroenterology 1995; 108: 470-6.
33. Yamamoto AM, Cresteil D, Boniface O, Clerc FF, Alvarez F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur: J. Immunol. 1993; 23: 1105-111.
34. Jarasch ED, Kartenberg J, Bruder G et al. B-types cytochromes in plasma membrane isolated from rat liver, in comparison with those from endomembranes. J. Cell Biol. 1979; 80: 37-52.
35. Staciecki P, Oesch F. Distribution of enzymes involved in metabolism of polycyclic aromatic hydrocarbons among rat liver endomembranes and plasma membranes. Eur. J. Cell Biol. 1980; 21: 79-92.
36. Lenzi M, Bianchi B, Casani F et al. Liver cell surface expression of the antigen reacting with liver-kidney microsomal antibody (LKM). Clin. Exp. Immunol. 1984; 55: 36-40.
37. De Lemos-Chiandini C, Alvarez F, Bernard O et al. Determination of the membrane topology of the phenobarbital-inducible rat liver cytochrome P450 isoenzyme PB-4 using site-specific antibodies. J. Cell Biol. 1987; 104: 209-19.
38. Satoh H, Gillette JR, Davies HW, Schulick RD, Pohl LR. Immunochemical evidence of trifluoroacetylated cytochrome P450 in the liver of halothane treated rats. Mol. Pharmacol. 1985; 28: 468-74.
39. Trautwein C, Gerken G, Meyer zum Büschenfelde KH, Manns MP. Lack of surface expression for the B-cell autoepitope of cytochrome P450 2D6 evidenced by flow cytometry. Ztschr Gastroenterologie 1993; 31: 225-30.
40. Wu D, Cederbaum AI. Presence of functionally active cytochrome P4502E1 in the plasma membrane of rat hepatocytes. Hepatology 1992; 15: 515-24.
41. Loeper J, Descartoire V, Maurice M et al. Presence of functional cytochrome P450 on isolated rat hepatocyte plasma membrane. Hepatology 1990; 11: 850-8.
42. Robin MA, Maratrat M, Loeper J et al. Cytochrome P450 2B follows a vesicular route to the plasma membrane in cultured rat hepatocytes. Gastroenterology 1995; 108: 1110-23.
43. Homberg JC, Andre C, Abuaf N. A new anti-liver/kidney-microsome antibody (anti-LKM2) in tienilic induced hepatitis. Clin. Exp. Immunol. 1984; 55: 561-70.
44. Beaune PH, Dansette PM, Mansuy D et al. Human antiendoplasmic reticulum auto-antibodies appearing in a drug-induced hepatitis directed against a human liver cytochrome P450 that hydroxylates the drug. Proc. Natl Acad. Sci. USA 1987; 84: 551-5.
45. Durazzo M, Philipp T, van Pelt FNAM et al Heterogeneity of microsomal auto-antibodies (LKM) in chronic hepatitis C and D virus infection. Gastroenterology 1995; 108: 455-62.
46. Obermayer-Straub P, Strassburg CP, Clemente MG, Philipp T, Tukey RH, Manns MP. Recognition of three different epitopes on UDP-glucuronosyltransferases by LKM-3 antibodies in patients with autoimmune hepatitis and hepatitis D. 4th United European Gastroenterology Week, ICC Berlin. Gut 1995; 37: A100.
47. Strassburg CP, Obermayer-Straub P, Alex B et al. Auto-antibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 1996; 111: 1582-92.
48. Straub P, Philipp T, Lamb JG et al. Molecular characterization of a microsomal antigen in hepatitis D. 45th Annual Meeting of the American Association for the Study of Liver Diseases. Hepatology 1994; 20: 427.
49. Crivelli O, Lavarini C, Chiaberge E et al. Microsomal auto-antibodies in chronic infection with HBsAg associated delta (d) agent. Clin. Exp. Immunol. 1983; 54: 232-8.
50. Bourdi M, Larrey D, Nataf J et al Anti-liver endoplasmatic reticulum auto-antibodies are directed against human cytochrome P450 IA2: A specific marker of dihydralazine-induced hepatitis. J. Clin. Invest. 1990; 85: 1967-73.
51. Manns MP, Griffin KJ, Quattrochi L et al. Identification of cytochrome P450 1A2 as a human autoantigen. Arch. Biochem. 1990; 280: 229-32.
52. Clemente MG, Obermayer-Straub P, Meloni A et al. Auto-antibodies against cytochrome P450 1A2 in a patient with liver disease in autoimmune polyendocrine syndrome type 1. 30th Annual Meeting of the European Association of the Study of the Liver, Copenhagen. J. Hepatol. 1995; 23 (Suppl. 1): 126.
53. Wächter B, Kyriatsoulis A, Lohse AW, Gerken G, Meyer zum Bueschenfelde KH, Manns MP. Characterisation of liver cytokeratin as a major target antigen of anti-SLA antibodies. J. Hepatol, 1990; 11: 232-9.
54. McFarlane IG, McFarlane BM, Major GN, Tolley P, Williams R. Identification of the hepatic asialoglycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin. Exp. Immunol. 1985; 55: 347-54.
55. Lohse AW, Manns M, Dienes HP, Meyer zum Büschenfelde KH, Cohen IR. Experimental autoimmune hepatitis: Disease induction, time course and T cell reactivity. Hepatology 1990; 11: 24-30.
56. Lohse AW, Kogel M, Meyer zum Bueschenfelde KH. Evidence for spontaneous immunosuppression in autoimmune hepatitis. Hepatology 1995; 22: 381-8.
57. Vergani D, Wells L, Larcher VF et al. Genetically determined low C4: A predisposing factor to autoimmune chronic active hepatitis. Lancet 1985; 2: 294-8.
58. Löhr H, Manns M, Kyriasoulis A et al. Clonal analysis of liver infiltrating T cells in patients with chronic active hepatitis (AI-CAH). Clin. Exp. Immunol. 1991; 84: 297-302.
59. Wen Li-Peakman M, Lobo-Yeo A, McFarlane BM, Mowat AP, Mieli-Vergani G, Vergani D. T cell directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet 1990; 336: 1527-30.
60. Mackay IR, Morris PJ. Association of autoimmune chronic hepatitis with HLA-A1-B8. Lancet 1972; 2: 793-5.
61. Tait B, Mackay IR, Board PH, Coggan M, Emery P, Eckardt G. HLA A1, B8, DR3 extended haplotypes in autoimmune chronic hepatitis. Gastroenterology 1989; 97: 479-81.
62. Manns M, Krüger M. Genetics in liver diseases. Gastroenterology 1994; 106: 1676-97.
63. Donaldson PT, Doherty DG, Hayliar KM et al. Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR 4 and A1-B8-Dr-3 are independent risk factors. Hepatology 1991; 13: 701-6.
64. Doherty DG, Donaldson PT, Underhill JA et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994; 19: 609-15.
65. Czaja AJ, Rakela J, Hay JE et al. Clinical and prognostic implications of human leucocyte antigen B8 in corticosteroid-treated severe chronic active hepatitis. Gastroenterology 1990; 98: 1587-93.
66. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993; 105: 1502-7.
67. Czaja AJ, Strettell MDJ, Thomson LJ et al. Association between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1996; 24: 232A.
68. Marcos Y, Fainboim HA, Capucchio M et al. Twolocus involvement in the association of human leucocyte antigen with the extrahepatic manifestation of autoimmune chronic active hepatitis. Hepatology 1994; 19: 1371-4.
69. Seki T, Kiyosawa K, Inoko H, Ota M. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology 1990; 12: 1300-4.
70. Vergani D, Wells L, Larcher VF et al. Genetically determined low C4: A predisposing factor to autoimmune chronic active hepatitis. Lancet 1985; 2: 294-8.
71. Scully LJ, Toze C, Sengar DPS, Goldstein R. Early onset autoimmune hepatitis is associated with a C4A gene deletion. Gastroenterology 1993; 104: 1478-84.
72. Manns M, Jentsch M, Mergener K et al. HLA class I-III in autoimmune hepatitis type 2 and its association with hepatitis C infection (Abstract) J. Hepatol. 1991; 16 (Suppl. 1): 16.
73. Lenzi M, Mantovani W, Cataleta M et al. HLA typing in autoimmune hepatitis (AI-CAH) type 2. J. Hepatol. 1992; 16: 59.
74. Doherty DG, Donaldson PT, Underhill JA et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994; 19: 609-15.
75. Strettell MDJ, Czaja A, Thomson LJ et al Susceptibility to autoimmune hepatitis (AIH) is determined by a lysine residue at position 71 of the DR (polypeptide chain, abstracts of the American Gastroenterological Association. Gastroenterology 1996; 110: A1335.
76. Seki T, Kiyosawa K, Ota M et al. Association of primary biliary cirrhosis with human leucocyte antigen DPB1*0501 in Japanese patients. Hepatology 1993; 18: 73-8.
77. Ota M, Seki T, Kiyosawa K et al. A possible association between basic amino acids at position 13 of DRB1 chains and autoimmune hepatitis. Immunogenetics 1992; 36: 49-55.
78. Chen DF, Tillmann HL, Endres W et al. High frequency of HLA DRB1*0301 and its extended hapolotype in soluble liver antigen-antibody positive autoimmune hepatitis. Hepatology 1996; Suppl.: 232A.
79. Vento S, Garofano T, Di Perri G, Dolci L, Concia E, Bassetti D. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991; 337: 1183-7.
80. Laskus T, Slusarczyk J. Autoimmune chronic active hepatitis developing after acute type B hepatitis. Dig. Dis. Sci. 1989; 34: 1294-7.
81. Hopf U, Möller B. Die Entwicklung chronisch aktiver Hepatitis vom autoimmunen Typ nach Hepatitis-B-Virus Infektion mit HBsAg Persistenz. Vier Kasuistiken. Z. Gastroenterol. 1984; 22: 121-8.
82. Lenzi M, Johnson PJ, McFarlane IG et al. Antibodies to hepatitis C virus in autoimmune liver disease; evidence for geographical heterogeneity. Lancet 1991; 338: 277-80.
83. Michel G, Ritter A, Gerken G et al. Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet 1992; 339: 267-9.
84. Lunel F, Abuaf N, Frangeul L et al. Liver-kidney microsomes antibody type 1 and hepatitis C virus infection. Hepatology 1992; 16: 630-6.
85. Strassburg CP, Manns MP. Viral hepatitis and autoimmunity: chicken or egg? Viral Hepatitis 1995; 1: 97-102.
86. Heringlake S, Tillmann HL, Cordes-Temme R, Trautwein C, Hunsmann G, Manns MP. GBV-C is not the major cause of autoimmune hepatitis. J. Hepatol. 1996; 25: 980-4.
87. Robertson Da, Zhang SL, Guy EC, Wright R. Persistent measles virus genome in autoimmune chronic active hepatitis. Lancet 1987; 2: 9-11.
88. Vento S, Guella L, Mirondola F et al. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 1995; 346: 608-9.
89. Odievre AM, Maggiore C, Homberg JC et al. Seroimmunologic classification of chronic hepatitis in 57 children. Hepatology 1983; 3: 407-9.
90. Philipp T, Durazzo M, Trautwein C et al. LKM-3 auto-antibodies in chronic hepatitis D recognize the UDP-glucuronosyltransferases. Lancet 1994; 344: 578-81.
91. Bourdi M, Tinel M, Beaune PH, Pessayre D. Interactions of dihydralazine with cytochromes P4501A: A possible explanation for the appearance of anti-P450 1A2 auto-antibodies. Mol. Pharmacol. 1994; 45: 1287-95.
92. Treichel U, Poralla T. The asialoglycoprotein receptor (ASGP R) as hepatic autoantigen. In: Meyer zum Büschenfelde KH, Hoofnagle J, Manns M, eds. Immunology and Liver. London: Kluwer Academic Publishers, 1993; 233-9.
93. Kirk AP, Jain S, Pocock S et al. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980; 21: 78-93.
94. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N. Engl. J. Med. 1995; 333: 958-63.
95. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom A, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992; 15: 215-21.
96. Wright HL, Bou-Abboud CF, Hassanein T et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 1992; 53: 136-9.
97. Neuberger J, Portmann B, Calne R, Williams R. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 1984: 37: 363-5.
98. Danielson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment. Pharmacol. Ther. 1994; 8: 585-90.
99. Schüler A, Manns MP. Treatment of autoimmune hepatitis. In: Arroyo V, Bosch J, Rodés J, eds. Treatment in Hepatology. SA: Masson, 1995; 375-83.
100. Ahonen P, Myllrniemi S, Sipil I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N. Engl. J. Med. 1990; 322: 1829-36.
101. Neufeld M, Maclaren N, Blizzard R. Autoimmune polyglandular syndromes. Ped. Ann. 1980; 9: 154-62.
102. Riley WJ. Autoimmune polyglandular syndromes. Hormone Research 1982; 38 (Suppl. 2): 9-15.
103. Ahonen P, Koskimies S, Lokki ML, Tiilikainen A, Perheentupa J. The expression of autoimmune polyglandular disease type I appears associated with several HLA-A antigens but not with HLA-DR. J. Clin. Endocrinol. Metab. 1988; 66: 1152-7.
104. Altonen J, Bjorses P, Sadkuijl L, Perheentupa J, Peltonen L. An autosomal locus causing autoimmune disease: Autoimmune polyglandular disease type 1 assigned to chromosome 21. Nature Genetics 1994; 8: 83-7.
105. Arulantham K, Dwyer JM, Genel M et al. Evidence for defective immunoregulation in the syndrome of familial candidiasis endocrinopathy. N. Engl. J. Med. 1979; 300: 164-8.
106. Sacher M, Blumel P, Thaler H, Manns M. Chronic active hepatitis associated with vitiligo, nail dystrophy, alopecia and a new variant of LKM antibodies. J. Hepatol. 1990; 10: 364-9.
107. Agnello V, Chung RT, Kaplan L. A role of hepatitis C virus infection in type II cryoglobulinemia. N. Engl. J. Med. 1992; 19: 1490.
108. Cacoub P, Lunel-Fabiani F, Huong Du LT et al. Polyarthritis nodosa and hepatitis C infection. Ann. Intern. Med. 1992; 116: 605-6.
109. Fargion S, Peperno A, Cappellini MD et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992; 16: 1322-6.
110. Haddad J, Deny P, Munz-Gotheil C et al. Lymphocyticsialadenitis of Sjörgen's syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339: 321-3.
111. DeCastro M, Sanchez J, Herrera JF et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993; 17: 551-7.
112. Ferri C, Greco F, Longombardo G et al. Association between hepatitis C virus and mixed cryoglobulinemia. Clin. Exp. Rheumatol. 1991; 9: 621-4.
113. Tran A, Quaranta JF, Benzaken S et al. High prevalence of thyroid antibodies in a prospective series of patients with chronic hepatitis C. Hepatology 1993; 18: 253-7.
114. Pawlotsky JM, Ben Yahia M, Andre C et al. Immunological disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology 1994; 19: 841-8.
115. Michiro S, Hoshi Y, Takeda K et al. Non A, non B hepatitis specific antibodies directed at host derived epitope: implication for an autoimmune process. Lancet 1990; II: 1400-3.
116. Muratori L, Lenzi M, Caaleta M et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J. Hepatol. 1994; 21: 199-203.
117. Todros L, Saracco G, Durazzo M et al. Efficacy and safety of interferon alpha therapy in chronic hepatitis C with auto-antibodies to liver kidney microsomes. Hepatology 1995; 22: 1374-8.
118. Ma Y, Lenzi M, Gerken J et al. The target antigen of liver kidney microsomal antibody is different in type II autoimmune chronic active hepatitis and chronic hepatitic C virus infection. J. Hepatol. 1992; 16: 4.
119. Yamamoto AM, Mura C, De Lemos-Chiardini C et al. Cytochrome P450 2D6 recognized by LKM1 antibody is not expressed on the surface of hepatocytes. Clin. Exp. Immunol. 1993; 92: 381-90.
120. Michitaka K, Durazzo M, Tillmann H et al. Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology 1994; 106: 1603-10.
121. Ritter JK, Chen F, Sheen YY et al. A novel complex locus UGT1 encodes human bilirubin, phenol and other UDP-glucuronosyltransferase isozymes with identical carbonyl termini. J. Biol. Chem. 1992; 267: 3257-61.
122. Guengerich FP. Cytochrome P450 enzymes. American Scientist 1993; 81: 440-7.
123. Beaune PH, Pessayre D, Dansette P et al. Auto-antibodies against cytochromes P450: Role in Human Diseases. Adv. Pharmacol. 1994; 30: 199-245.
124. Pessayre D. Toxic and immune mechanisms leading to acute and subacute drug-induced liver injury. In: Miguet JP and Dhumeaux D, eds. Progress in Hepatology. Paris: John Libbey Eurotext, 1993; 23-39.
125. Zimmerman HJ, Lewis JH, Ishak KG, Maddrey W. Ticrynafen-associated hepatic injury: Analysis of 340 cases. Hepatology 1984; 4: 315-23.
126. Homberg JC, Abuaf N, Hemly Khalid et al. Drug-induced hepatitis associated with anticytoplasmic organelle auto-antibodies. Hepatology 1985; 5: 722-5.
127. Stricker BHC. In: Stricker, ed. Drug-Induced Hepatic Injury BHC. Amsterdam: Elsevier, 1992.
128. Roschlau G. Virushepatitis gegen Arzneimittelhepatitis. Z. Klin. Med. 1986; 41: 817-19.
129. Siegmund W, Franke G, Biebler et al. The influence of the acetylator phenotype on the clinical use of dihydralazine. Int. J. Clin. Pharm. Ther. Toxicol. 1985; 23: S74-8.
130. Reinhardt M, Machnik G, Krombholz B, Jahn G. Die sogenannte Dihydralazin-Hepatitis. Ein Beitrag zur Pathogenese. Dtsch. Z. Verdau. Stoffwchslkr. 1985; 45: 283-94.
131. Roschlau G. Hepatitis mit konfluierenden Nekrosen durch Dihydralazin (Depressant) Zentrbl. Allg. Pathol: Anat. 1983; 127: 385-93.
132. Kunze KD, Porst H, Tschöppel L. Morphology and pathogenesis of liver injury produced by dihydralazine, propranolol and ketrophenylbutazone. Zentralbl. Allg. Pathol. 1985; 130: 509-18.
133. Bourdi M, Gautier JC, Micheva J et al. Anti-liver microsomes auto-antibodies and dihydralazune induced hepatitis: Specificity of auto-antibodies and inductive capacity of the drug. Mol. Pharmacol. 1992; 42: 280-5.
134. Desmet V, Gerber MA, Hoofnagle JH, Manns M, Scheuer P. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994; 9: 1513-20.
135. Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450 2D6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993; 105: 1522-8.
136. Jeffers J, Hasan F, de Medina M et al. Prevalence of antibodies to hepatitis C virus among patients with cryptogenic hepatitis and cirrhosis. Hepatology 1992; 15: 187-90.
137. Brunner G, Klinge O. Ein der chronisch-destruierenden nicht-eitrigen Cholangitis ähnliches Krankheitsbild mit antinukleären Antikörpern (Immuncholangitis). Dtsch. Med. Wschr. 1987; 12: 1454-8.
138. Berg PA, Sayer T, Wiedmann KH, Klöppel G, Lindner H. Serological classification of chronic cholestatic liver disease by the use of two different types of antimitochondrial antibodies. Lancet 1980; ii: 1329-32.
139. Davis PA. M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: Epitopes or epithenomena? Hepatology 1992; 16: 1128-36.
140. Yeaman SJ, Fussey SP, Danner DJ, James OF, Mutimer DJ, Bassendine MF. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988; 1: 1067-70.
141. Mieli-Vergani G, Lobo-Yeo A, McFarlane BM et al. Different immune mechanisms leading to autoimmunity in primary sclerosing cholangitis and autoimmune chronic active hepatitis of childhood. Hepatology 1989; 9: 198-203.